EQL Pharma: Report from the Annual General Meeting of EQL Pharma AB (publ) on May 15th, 2017

Read as pdf

At EQL Pharma's Annual General Meeting, which was held in Lund, May 15th, 2017, the following decisions were made:

Adoption of the balance sheet and income statement, disposition regarding the Company’s results

The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2016. The annual general meeting also resolved that no dividends shall be paid for the financial year 2016.

Discharge from liability for the Board of Directors and the Managing Director

The annual general meeting discharged the board members and the managing director from liability for the financial year 2016.

Board of directors and auditor

The AGM resolved to re-elect Board members Björn Beermann Christer Fåhraeus, Lars Holmqvist, Ingemar Kihlström, Rajiv I Modi and Maria Öhlander. It was decided to elect Ingemar Kihlström as Chairman of the Board. Crowe Horwarth Osborne AB was elected as auditing firm, with Olov Strömberg as auditor in charge.

The annual general meeting resolved that fees to the Board shall be unchanged since last year, i.e.e SEK 170,000 to the Chairman of the Board and SEK 70,000 each to the remaining board members and that no Board fees shall be paid to Board members who are CEO. It was resolved that remuneration to the auditors shall be paid in accordance with approved invoices.

Amendment of articles of association

The AGM decided, pending approval of the Swedish tax authorities, to extend the current fiscal year until 2018-03-31 to facilitate the consolidation of companies in the Group. The proposal will now be forwarded to the Swedish tax authorities, which is the final decision point.

Resolution regarding principles for the appointment of a nomination committee, how members of the nomination committee are to be appointed and the tasks of the nomination committee

The annual general meeting resolved to adopt the principles proposed by the nomination committee for appointment of a nomination committee, how members of the nomination committee are to be appointed and the tasks of the nomination committee. The AGM's decision is in accordance with the proposal presented in the notice.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

EQL Pharma AB (publ) in brief

EQL Pharma is specialized in developing and selling generic drugs, ie drugs that are medically equivalent to the original medicines. The company currently markets five niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently focused entirely on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs 7 (8) people and is listed on AktieTorget. EQL Pharma conducts extensive development in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.


Read as pdf  Further information about EQL Pharma

Publicerat: 5/17/2017 1:45:15 PM

Nyheten distribueras av AktieTorget i samarbete med Cision.
För att prenumerera på nyheter på detta bolag, klicka här.
 

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se